Newron Pharmaceuticals SpA (FRA:NP5) 3-Month Share Buyback Ratio: 0.00% (As of Dec. 2025 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:NP5 Newron Pharmaceuticals SpA FRA:NP5
76 GF Score
Price €13.75
GF Value €14.66
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Newron Pharmaceuticals SpA 3-Month Share Buyback Ratio?

Newron Pharmaceuticals SpA FRA:NP5 +8.70% 76 3-Month Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus rates FRA:NP5 with a GF Score™ of 76/100 and a GF Value™ of €14.66 (Fairly Valued). The stock has 5 warning signs investors should review.

3-Month Share Buyback Ratio only apply to companies whose reporting frequency is 3 months.

FRA:NP5
76GF Score
Newron Pharmaceuticals SpA FRA:NP5
3-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a 3-Month Share Buyback Ratio of 0.00 mean?
Newron Pharmaceuticals SpA (FRA:NP5) has a 3-Month Share Buyback Ratio of 0.00 as of Dec. 2025. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Newron Pharmaceuticals SpA and its competitors.
Is Newron Pharmaceuticals SpA's 3-Month Share Buyback Ratio too high?
Newron Pharmaceuticals SpA's current 3-Month Share Buyback Ratio is 0.00. Overall, Newron Pharmaceuticals SpA has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Newron Pharmaceuticals SpA's 3-Month Share Buyback Ratio compare to VRTX and REGN?
Newron Pharmaceuticals SpA's 3-Month Share Buyback Ratio of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Biotechnology company?
A good 3-Month Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Newron Pharmaceuticals SpA and its competitors. Newron Pharmaceuticals SpA's current 3-Month Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newron Pharmaceuticals SpA stock overvalued right now?
Based on GuruFocus' analysis, Newron Pharmaceuticals SpA (FRA:NP5) is currently considered Fairly Valued. The stock's GF Value™ is €14.66, compared to a current price of €13.75 — trading 6.2% below its estimated fair value. The current 3-Month Share Buyback Ratio is 0.00. Newron Pharmaceuticals SpA's overall GF Score™ is 76/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For Newron Pharmaceuticals SpA (FRA:NP5), the current 3-Month Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Newron Pharmaceuticals SpA (FRA:NP5) Overvalued in 2026?

Based on GuruFocus' analysis, Newron Pharmaceuticals SpA stock appears to be undervalued. The current stock price of €13.75 is trading 6.2% below its estimated GF Value™ of €14.66. GuruFocus considers Newron Pharmaceuticals SpA to be Fairly Valued.

Key valuation signals for FRA:NP5:

  • 3-Month Share Buyback Ratio: 0.00
  • GF Value™: €14.66 vs. price of €13.75 (6.2% below fair value)
  • GF Score™: 76/100 with 5 warning signs

No single metric tells the full story. See the FRA:NP5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Newron Pharmaceuticals SpA Business Description

Address Via Antonio Meucci 3, Bresso, Milan, ITA, 20091
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.
76GF Score

Get the complete analysis for FRA:NP5

3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.75
Price
€14.66
GF Value